Could Single-anastomosis Gastric Bypass Be a Curative Treatment for Type II Diabetes?

From Diabetes Care to Diabetes Cure; Could Single-anastomosis Gastric Bypass Be a Safe Bridge to Reach This Target in Non-Obese Patients?

Status

Suspended

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03412253

Enrollment

Registered

2018-01-26

Start date

2013-11-01

Completion date

2018-02-04

Last updated

2018-01-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic Surgery

Keywords

metabolic surgery, BMI 25-30 kg/m2, SAGB, T2DM remission.

Brief summary

Single- Anastomosis gastric bypass (SAGB) is a potentially curative line of treatment for type II diabetes mellitus (T2DM) patients with BMI 25-30 kg/m2. Accordingly, SAGB could be integrated into T2DM treatment algorithm

Detailed description

Background: T2DM has been considered as a chronic progressive incurable metabolic disease. Single-anastomosis gastric bypass (SAGB) was shown to be effective in obese patients in terms of weight reduction and T2DM remission, yet its effect on non-obese diabetics is not extensively studied. In this study, we tried to determine the anthropometric and glycemic outcomes of SAGB as a proposed line of treatment for type II diabetes mellitus (T2DM) patients with body mass index (BMI) 25-30 kg/m2. Methods: From November 2013 to March 2016, a prospective study has been conducted at Ain-Shams University hospitals on 17 consecutive patients undergone SAGB. The demographic and anthropometric data of the patients, as well as their relevant laboratory results, were reported, other data including anti-diabetic medications, co-morbid metabolic diseases were also assessed. All patients were scheduled for laparoscopic SAGB and were advised to come in regular follow up at 1, 3, 6, 12 and 18 months postoperatively. T2DM Remission is considered if glycosylated hemoglobin (HbA1c) \<6.5 % and fasting plasma glucose (FPG) \< 126 mg/dl for at least 1 year without medication.

Interventions

PROCEDURESingle-Anastomosis Gastric Bypass surgery (SAGB).

We checked the effect of SAGB on patients suffered from T2DM with BMI 25-30

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

20 Years to 60 Years

Healthy volunteers

Inclusion criteria

.Type II diabetic patients. * Age: 20-60 years. * either gender.

Exclusion criteria

* Previous bariatric surgery. * Controlled T2DM. * Duration of T2DM \>10 years. * Patients with endocrinal diseases, * Pregnancy. * Those unfit for general anesthesia.

Design outcomes

Primary

Measure	Time frame	Description
Cure of type II DM.	1Year	T2DM Remission is considered if glycosylated hemoglobin (HbA1c) \<6.5 % and fasting plasma glucose (FPG) \< 126 mg/dl for at least 1 year without medication.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026